How it works:
Methoxsalen (a psoralen) intercalates with epidermal DNA; upon UVA exposure forms photo-adducts that stimulate melanogenesis and may modulate abnormal keratinocyte proliferation.
Enhances re-pigmentation in depigmented patches and increases the efficacy of targeted PUVA therapy.
Allows local treatment, reducing systemic exposure to psoralens.
Who it’s for (prescriber-directed):
Patients with localised vitiligo patches.
Individuals undergoing dermatology-supervised PUVA for small-area psoriasis.
Selected pigmentary disorders where controlled photosensitisation is indicated.
Those preferring topical over oral psoralen when clinically suitable.
Vitiligo (segmental or focal lesions).
Adjunct to UVA/PUVA regimens in psoriasis (localised plaques).
Other dermatological uses requiring topical photosensitiser at clinician discretion.
Apply a thin film to affected skin only, as directed by your dermatologist, typically 30–60 minutes before scheduled UVA exposure (timing may vary by protocol). Avoid application to unaffected skin; remove excess if instructed. Undergo controlled UVA treatment exactly as prescribed and use protective eyewear and sun avoidance for the remainder of the day.
Known hypersensitivity to methoxsalen/psoralens.
Disorders with inherent photosensitivity (e.g., porphyrias).
Current or history of skin cancer or premalignant lesions in treatment area.
Severe sunburn or active inflammatory skin disease at application sites.
Pregnancy & lactation: use only if potential benefit justifies potential risk (specialist decision).
Paediatric use: specialist guidance required.
Local erythema, warmth, stinging or itching.
Photodermatitis, blistering with excessive UVA.
Irregular hyperpigmentation of surrounding skin.
Rare: marked phototoxicity, vesiculation, long-term photoageing with repeated misuse.
